Locoregional Therapies for Hepatocellular Carcinoma: What Has Changed in the Past Ten Years?

Anjana A Pillai; Meera Ramanathan; Laura Kulik

doi:10.1016/j.cld.2020.07.011

Locoregional Therapies for Hepatocellular Carcinoma: What Has Changed in the Past Ten Years?

Clin Liver Dis. 2020 Nov;24(4):681-700. doi: 10.1016/j.cld.2020.07.011.

Authors

Anjana A Pillai¹, Meera Ramanathan², Laura Kulik³

Affiliations

¹ Department of Internal Medicine, University of Chicago Medicine, 5841 South Maryland Avenue, Chicago, IL 60687, USA.
² Department of Internal Medicine, Northwestern Memorial Hospital, 676 North St. Clair 19(th) Floor, Chicago, IL 60611, USA.
³ Department of Internal Medicine, Northwestern Memorial Hospital, 676 North St. Clair 19(th) Floor, Chicago, IL 60611, USA. Electronic address: lkulik@nm.org.

PMID: 33012453
DOI: 10.1016/j.cld.2020.07.011

Abstract

The evolution of locoregional therapies in the last decade has been refined with improved patient selection and a development of a more personalized approach. In doing so, there has been associated improved outcomes and less toxicity. With the rapidly changing landscape of systemic therapy, the role of locoregional therapies alone or in combination for downstaging and curative intent will continue to evolve.

Keywords: HCC; Liver cancer; Locoregional therapy; Systemic therapy; TACE; TARE; Y90.

Publication types

Review

MeSH terms

Ablation Techniques*
Brachytherapy*
Carcinoma, Hepatocellular / therapy*
Chemoembolization, Therapeutic*
Hepatectomy
Humans
Liver Neoplasms / therapy*
Liver Transplantation
Radiosurgery*
Radiotherapy